Literature DB >> 9462508

LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator.

D N Mauri1, R Ebner, R I Montgomery, K D Kochel, T C Cheung, G L Yu, S Ruben, M Murphy, R J Eisenberg, G H Cohen, P G Spear, C F Ware.   

Abstract

Herpes simplex virus (HSV) 1 and 2 infect activated T lymphocytes by attachment of the HSV envelope glycoprotein D (gD) to the cellular herpesvirus entry mediator (HVEM), an orphan member of the tumor necrosis factor receptor superfamily. Here, we demonstrate that HVEM binds two cellular ligands, secreted lymphotoxin alpha (LTalpha) and LIGHT, a new member of the TNF superfamily. LIGHT is a 29 kDa type II transmembrane protein produced by activated T cells that also engages the receptor for the LTalphabeta heterotrimer but does not form complexes with either LTalpha or LTbeta. HSV1 gD inhibits the interaction of HVEM with LIGHT, and LIGHT and gD interfere with HVEM-dependent cell entry by HSV1. This characterizes herpesvirus gD as a membrane-bound viokine and establishes LIGHT-HVEM as integral components of the lymphotoxin cytokine-receptor system.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9462508     DOI: 10.1016/s1074-7613(00)80455-0

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  244 in total

Review 1.  Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors.

Authors:  B G Darnay; B B Aggarwal
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry.

Authors:  D B Anderson; S Laquerre; K Ghosh; H P Ghosh; W F Goins; J B Cohen; J C Glorioso
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  Localization of the gD-binding region of the human herpes simplex virus receptor, HveA.

Authors:  J C Whitbeck; S A Connolly; S H Willis; W Hou; C Krummenacher; M Ponce de Leon; H Lou; I Baribaud; R J Eisenberg; G H Cohen
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

4.  Turning on LIGHT.

Authors:  S W Granger; C F Ware
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

5.  Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes.

Authors:  Lisa Yan; Diane M Da Silva; Bhavna Verma; Andrew Gray; Heike E Brand; Joseph G Skeate; Tania B Porras; Shreya Kanodia; W Martin Kast
Journal:  Prostate       Date:  2014-11-14       Impact factor: 4.104

6.  Differential expression of LIGHT and its receptors in human placental villi and amniochorion membranes.

Authors:  Ryan M Gill; Jian Ni; Joan S Hunt
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

7.  Excess LIGHT contributes to placental impairment, increased secretion of vasoactive factors, hypertension, and proteinuria in preeclampsia.

Authors:  Wei Wang; Nicholas F Parchim; Takayuki Iriyama; Renna Luo; Cheng Zhao; Chen Liu; Roxanna A Irani; Weiru Zhang; Chen Ning; Yujin Zhang; Sean C Blackwell; Lieping Chen; Lijian Tao; M John Hicks; Rodney E Kellems; Yang Xia
Journal:  Hypertension       Date:  2013-12-09       Impact factor: 10.190

Review 8.  TNF superfamily: costimulation and clinical applications.

Authors:  Dass S Vinay; Byoung S Kwon
Journal:  Cell Biol Int       Date:  2009-02-20       Impact factor: 3.612

9.  TRAF2 plays a key, nonredundant role in LIGHT-lymphotoxin beta receptor signaling.

Authors:  You-Sun Kim; Sergei A Nedospasov; Zheng-Gang Liu
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

10.  Distinct roles for lymphotoxin-alpha and tumor necrosis factor in the control of Leishmania donovani infection.

Authors:  Christian R Engwerda; Manabu Ato; Simona Stäger; Clare E Alexander; Amanda C Stanley; Paul M Kaye
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.